Neuroplasticity as a target for the pharmacotherapy of anxiety disorders, mood disorders, and schizophrenia

被引：58

作者：

Krystal, John H. ^{[1
,2
,3
]}

Tolin, David F. ^{[1
,4
]}

Sanacora, Gerard ^{[1
,3
]}

Castner, Stacy A. ^{[1
,2
,5
]}

Williams, Graham V. ^{[1
,2
,5
]}

Aikins, Deane E. ^{[1
,2
]}

Hoffman, Ralph E. ^{[1
,6
]}

D'Souza, D. Cyril ^{[1
,2
,3
]}

机构：

[1] Yale Univ, Dept Psychiat, Sch Med, New Haven, CT 06510 USA

[2] VA Connecticut Healthcare Syst, West Haven, CT 06516 USA

[3] Connecticut Mental Hlth Ctr, Abraham Ribicoff Res Facil, New Haven, CT 06519 USA

[4] Hartford Hosp, Inst Living, Hartford, CT 06115 USA

[5] Yale Univ, Dept Neurobiol, Sch Med, New Haven, CT 06510 USA

[6] Yale New Haven Med Ctr, Hosp Psychiat, New Haven, CT 06504 USA

来源：

DRUG DISCOVERY TODAY | 2009年 / 14卷 / 13-14期

关键词：

TRANSCRANIAL MAGNETIC STIMULATION; POSTTRAUMATIC-STRESS-DISORDER; DOPAMINE D-1 RECEPTOR; OBSESSIVE-COMPULSIVE DISORDER; COGNITIVE-BEHAVIORAL THERAPY; RANDOMIZED CONTROLLED-TRIAL; MOTOR CORTEX EXCITABILITY; FEAR-POTENTIATED STARTLE; LONG-TERM POTENTIATION; D-ASPARTATE RECEPTORS;

D O I：

10.1016/j.drudis.2009.05.002

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Current treatments for psychiatric disorders were developed with the aim of providing symptomatic relief rather than reversing underlying abnormalities in neuroplasticity or neurodevelopment that might contribute to psychiatric disorders. This review considers the possibility that psychiatric treatments might be developed that target neuroplasticity deficits or that manipulate neuroplasticity in novel ways. These treatments might not provide direct symptomatic relief. However, they might complement or enhance current pharmacotherapies and psychotherapies aimed at the prevention and treatment of psychiatric disorders. In considering neuroplasticity as a target for the treatment of psychiatric disorders, we build on exciting new findings in the areas of anxiety disorders, mood disorders, and schizophrenia.

引用

页码：690 / 697

页数：8

共 50 条

[1] Pharmacotherapy for mood, anxiety, and cognitive disorders
Dunner, DL
[J]. JOURNAL OF CLINICAL PSYCHIATRY, 2000, 61 (09) : 682 - 682
[2] Pharmacotherapy for mood, anxiety, and cognitive disorders
Klein, DF
[J]. AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (01): : 165 - 166
[3] Pharmacotherapy for mood, anxiety, and cognitive disorders
Sumner, CR
[J]. PSYCHIATRIC SERVICES, 2000, 51 (12) : 1577 - 1577
[4] Pharmacotherapy for mood, anxiety, and cognitive disorders
Jacobsen, FM
[J]. DEPRESSION AND ANXIETY, 2002, 16 (03) : 135 - 136
[5] Pharmacotherapy of comorbid mood, anxiety, and substance use disorders
Brady, KT
Verduin, ML
[J]. SUBSTANCE USE & MISUSE, 2005, 40 (13-14) : 2021 - 2041
[6] Pharmacotherapy of mood disorders
Thase, Michael E.
Denko, Timothey
[J]. ANNUAL REVIEW OF CLINICAL PSYCHOLOGY, 2008, 4 : 53 - +
[7] Association of Strabismus With Mood Disorders, Schizophrenia, and Anxiety Disorders Among Children
Lee, Yoon H.
Repka, Michael X.
Borlik, Marcy F.
Velez, Federico G.
Perez, Claudia
Yu, Fei
Coleman, Anne L.
Pineles, Stacy L.
[J]. JAMA OPHTHALMOLOGY, 2022, 140 (04) : 373 - 381
[8] Neuroplasticity as a target for the pharmacotherapy of psychiatric disorders: New opportunities for synergy with psychotherapy
Krystal, John H.
[J]. BIOLOGICAL PSYCHIATRY, 2007, 62 (08) : 833 - 834
[9] Pharmacotherapy of Anxiety Disorders
Zwanzger, P.
[J]. FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2016, 84 (05) : 306 - 314
[10] PHARMACOTHERAPY OF ANXIETY DISORDERS
GOODMAN, WK
[J]. BIOLOGICAL PSYCHIATRY, 1994, 35 (09) : 620 - 620

← 1 2 3 4 5 →